FDA puts Parkinson’s trial on hold amid imaging abnormalities – BioWorld Online

Related Articles:

• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• BioWorld MedTech's Diagnostics Extra for Jan. 7, 2021 | 2021-01-07 | BioWorld - BioWorld Online January 7, 2021 BioWorld MedTech's Diagnostics Extra for Jan. 7, 2021 | 2021-01-07 | BioWorld  BioWorld Online
• BioWorld MedTech's Neurology Extra for Jan. 8, 2021 | 2021-01-08 | BioWorld - BioWorld Online January 8, 2021 BioWorld MedTech's Neurology Extra for Jan. 8, 2021 | 2021-01-08 | BioWorld  BioWorld Online
• BioWorld MedTech Patent Highlights: Week 53 | 2021-01-08 | BioWorld - BioWorld Online January 8, 2021 BioWorld MedTech Patent Highlights: Week 53 | 2021-01-08 | BioWorld  BioWorld Online
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Inflazome gets funding from Michael J. Fox Foundation for Parkinson's R&D - BioWorld Online March 26, 2019 Inflazome gets funding from Michael J. Fox Foundation for Parkinson's R&D  BioWorld OnlineBioWorld Online is the news *service* of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date ...
• Investors bullish on companies focused on neurological diseases - BioWorld Online May 11, 2019 Investors bullish on companies focused on neurological diseases  BioWorld OnlineBioWorld Online is the news *service* of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date ...
• Fountain Healthcare Partners closes third fund at $132M - BioWorld Online May 23, 2019 Fountain Healthcare Partners closes third fund at $132M  BioWorld OnlineBioWorld Online is the news *service* of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date ...
• Bayer goes all in on Bluerock, paying $240M up front for cell therapy firm - BioWorld Online August 8, 2019 Bayer goes all in on Bluerock, paying $240M up front for cell therapy firm  BioWorld OnlineBioWorld Online is the news *service* of record for the biotechnology industry and is updated every business morning. BioWorld Online will keep you up to date ...
• Beyond Clinic: How Can Imaging Help in the Diagnosis of Parkinson´s Disease? November 9, 2020 There is no simple way to diagnose the event-changing life of Parkinson´s disease (PD). Despite all the advancements in the biomarkers field, PD diagnosis still remains a clinical one based on the centrality of the motor features namely the presence of bradykinesia, rigidity, tremor and postural instability. However, non-motor symptoms are now considered in the PD diagnostic process as “supportive…
• Beyond Clinic: How Can Imaging Help in the Diagnosis of Parkinson´s Disease? November 9, 2020 There is no simple way to diagnose the event-changing life of Parkinson´s disease (PD). Despite all the advancements in the biomarkers field, PD diagnosis still remains a clinical one based on the centrality of the motor features namely the presence of bradykinesia, rigidity, tremor and postural instability. However, non-motor symptoms are now considered in the PD diagnostic process as “supportive…
• Monthly Research Review – December 2020 December 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly Research Review: Jaunary 2020 January 31, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during January 2020. The post is divided into seven parts based on the type of research: Basic biology, Disease mechanism, Clinical research, New clinical trials, Clinical trial news, Other news, and…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…
• Treatment with Stalevo and Comtan Does Not Raise Prostate Cancer Risk, FDA Finds August 22, 2019 A review by the U.S. Food and Drug Administration (FDA) found that Parkinson’s patients treated with medications containing entacapone are at no increased risk of prostate cancer. As such, the agency stands by its current recommendations for the use of Stalevo (entacapone/carbidopa/levodopa) and Comtan (entacapone; brand name is Comtess elsewhere) to ease motor problems in Parkinson’s disease. The FDA review was conducted after the findings…
• FDA and FTC Issue Joint Warning Letter to Company Selling Unproven CBD Products October 24, 2019 The Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) have issued a joint warning letter to Rooted Apothecary LLC, of Naples, Florida for illegally selling and advertising unapproved cannabidiol (CBD) products online with unsubstantiated health claims. The warning letter states that Rooted Apothecary falsely marketed their CBD products on their social media website and online store claiming…
• ALS: From ice bucket to centaur November 18, 2020 # # # # Amyotrophic lateral sclerosis (or ALS) is the third most common neurodegenerative condition. It is characterised by the loss of motor neurons, which leads to loss of muscle control. As with Parkinson’s, there is no cure for ALS, and there are only two FDA approved therapies for the condition. Recently, a biotech company – called Amylyx Pharmaceuticals…
• FDA gives nod to Boston Scientific's next-gen Vercise Genus DBS - BioWorld Online January 22, 2021 FDA gives nod to Boston Scientific's next-gen Vercise Genus DBS  BioWorld Online